Home Blog Page 15

VEGAIN Enters National Distribution

0

Independent Canadian sports nutrition brand VEGAIN has reached a major milestone in its growth journey. The company has secured national distribution through Raw Elements, launched a public equity crowdfunding campaign on FrontFundr, and introduced a patent-pending innovation: SURGE™ Clear Protein.

These developments mark VEGAIN’s transition from a fast-growing direct-to-consumer brand to a national player in the plant-based sports nutrition market.

Retail Expansion with Raw Elements
Through its new partnership with Raw Elements—one of Canada’s top natural health distributors—VEGAIN’s high-performance, 100% plant-based products will soon be available in retail locations across the country.

“Raw Elements is known for representing the best in natural health and sports nutrition. We’re thrilled to work with them to bring VEGAIN to more customers across Canada,” said Edan Wolk, Founder & CEO of VEGAIN.

“VEGAIN is a brand that resonates with today’s conscious consumer. It’s innovative, high-performance, and values-driven,” added Olivia Haddad, General Manager at Raw Elements.

Community Investment Now Open
VEGAIN has also launched an equity crowdfunding campaign on FrontFundr, allowing everyday Canadians to invest in the company.

“We’ve built this company alongside our community, and now they can truly be part of it,” said Wolk.

The capital raised will support national retail expansion, operational growth, and the upcoming commercial debut of SURGE™ Clear Protein.

Introducing SURGE™ Clear Protein
SURGE™ Clear Protein is a patent-pending innovation that redefines what vegan protein can be. Unlike traditional powders with thick textures and chalky mouthfeel, SURGE™ dissolves fully in water, delivering a clean, refreshing, juice-like drink. It is sugar-free, smooth, and free of bitterness—available as both a ready-to-mix powder and a ready-to-drink can.

This product addresses a growing demand for functional, clean-label, plant-based nutrition designed for modern lifestyles.

What’s Ahead
With national retail expansion, a growing base of community investors, and a new category-defining product, VEGAIN is entering its most exciting phase yet.

“We’re not here to ride the wave of plant-based nutrition—we’re here to lead it,” said Wolk.

About VEGAIN
VEGAIN is a Canadian independent sports nutrition brand offering 100% plant-based, high-performance products. Built on sustainability, innovation, and community, VEGAIN is redefining how active individuals fuel their performance.

About Raw Elements
Raw Elements is a Canadian distributor of premium natural health products, known for supporting innovative, ethically-driven brands in wellness, sports, and functional nutrition.

Red vs White Wine: Is One Riskier for Cancer? New Study Weighs In

0

For years, red wine has been held in high regard, and praised for its potential health benefits, particularly due to its rich antioxidant content. White wine, on the other hand, often lingers in the background of this debate, rarely receiving the same level of scrutiny. However, a recent study published in the journal Nutrients has challenged the assumption that red wine is the “healthier” choice—at least when it comes to cancer risk.

The study in question, a meta-analysis of observational research, examined whether there are any significant differences in cancer risk between red and white wine drinkers. The findings? Red and white wine appear to be equally carcinogenic, though white wine may pose a greater risk for skin cancer. Let’s dive deeper into the implications of this research and what it means for those who enjoy a glass of wine with dinner.

The Carcinogenic Effects of Alcohol

Alcohol has long been recognized as a carcinogen. The International Agency for Research on Cancer (IARC) classified alcoholic beverages as Group 1 carcinogens several decades ago, placing them in the same category as tobacco and asbestos. This means there is sufficient evidence to confirm that alcohol consumption directly contributes to cancer development.

In 2020, alcohol consumption was responsible for approximately 4.1% of global cancer cases, with bowel cancer and breast cancer being among the most commonly linked malignancies. The underlying mechanism is well understood: when alcohol is metabolized in the liver, it converts into acetaldehyde, a toxic compound that damages DNA and proteins, increasing the likelihood of mutations.

Despite these well-documented risks, many people continue to perceive red wine as a somewhat “healthier” alcoholic option, largely due to its polyphenol content. Compounds such as resveratrol, tannins, and flavonoids have been linked to potential health benefits, including anti-inflammatory and antioxidant effects. But do these benefits outweigh the risks? The latest research suggests otherwise.

New Study: Red vs White Wine and Cancer Risk

A recent meta-analysis published in Nutrients sought to answer a fundamental question: does drinking red wine pose a lower cancer risk compared to white wine? The researchers analyzed data from 42 observational studies, including both cohort and case-control studies, to determine if there were any significant differences in cancer risk based on the type of wine consumed.

Key Findings:

  • Overall Cancer Risk: The study found no significant difference between red and white wine consumption in terms of overall cancer risk. The relative risks (RRs) were 0.98 for red wine and 1.00 for white wine—essentially the same.
  • White Wine and Skin Cancer: White wine consumption was associated with a 22% increased risk of skin cancer compared to red wine. This was one of the most striking findings of the study.
  • Gender Differences: While no significant difference in cancer risk was observed between red and white wine in men, the association was significant in women. This suggests potential hormonal or metabolic factors at play.
  • Breast Cancer Risk: Both red and white wine were associated with an increased risk of breast cancer, with no notable difference in incidence rates between the two.
  • Dose-Response Analysis: When examining case-control data, researchers found that consuming an additional 10 grams of ethanol from red wine per day increased overall cancer risk by 5%. However, this association was not observed in cohort studies.

These findings challenge the widespread belief that red wine is the “healthier” choice simply because it contains more antioxidants. The study suggests that, at least in terms of cancer risk, red wine offers no protective benefit over white wine.

Why Might White Wine Be Linked to a Higher Skin Cancer Risk?

One of the most unexpected findings in this study was the increased risk of skin cancer associated with white wine consumption. While the exact mechanisms remain unclear, there are several potential explanations:

  1. Acetaldehyde Levels: White wine has been found to contain higher levels of acetaldehyde than red wine. Since acetaldehyde is a known carcinogen, this could contribute to an elevated cancer risk, particularly in tissues exposed to oxidative stress.
  2. Lack of Protective Polyphenols: Red wine contains significantly more polyphenols, such as resveratrol and tannins, which have been studied for their potential anticancer properties. White wine, being lower in these compounds, may not offer the same level of cellular protection.
  3. UV Sensitisation: Some studies have suggested that certain compounds in white wine could increase photosensitivity, making skin cells more vulnerable to damage from ultraviolet (UV) radiation. This could potentially contribute to an increased risk of skin cancer.

While further research is needed to confirm these hypotheses, the findings suggest that white wine drinkers may need to be particularly mindful of their sun exposure.

What Does This Mean for Wine Drinkers?

For those who enjoy the occasional glass of wine, this study serves as a sobering reminder that no form of alcohol is truly “safe” when it comes to cancer risk. While moderate wine consumption is often promoted for its potential cardiovascular benefits, the latest research reinforces that both red and white wine carry carcinogenic risks.

Should You Stop Drinking Wine?

That depends on individual health priorities. If reducing cancer risk is a primary concern, limiting alcohol intake—or avoiding it altogether—is the most effective strategy. The World Health Organization (WHO) has consistently stated that there is no safe level of alcohol consumption when it comes to cancer prevention.

If You Choose to Drink, Consider These Tips:

Limit Intake: Stick to the lowest possible amount. Current UK guidelines recommend no more than 14 units of alcohol per week (approximately 6 medium glasses of wine) spread over at least three days.

Stay Hydrated: Drinking plenty of water can help minimize some of the dehydrating effects of alcohol.

Prioritise Antioxidant-Rich Foods: If antioxidants are a concern, it’s far better to get them from whole foods like berries, nuts, and dark leafy greens rather than relying on wine.

Be Sun-Safe: If you’re a white wine drinker, be extra cautious with sun exposure. Wear sunscreen and protective clothing to minimize skin cancer risk.

 The Wine Myth Busted

The romanticized notion that red wine is a “health food” has been challenged time and time again, and this latest study is yet another nail in the coffin of that idea. While red wine does contain antioxidants, the carcinogenic effects of alcohol appear to outweigh any potential benefits. More importantly, this research highlights that white wine may pose an even greater risk for certain cancers, particularly skin cancer.

Ultimately, the decision to drink wine—or any alcoholic beverage—should be an informed one. If you choose to indulge, do so in moderation, but be aware that when it comes to cancer risk, neither red nor white wine gets a free pass.

Further Reading & References:

  • Lim, R. K., Rhee, J., Hoang, M., et al. (2025) Consumption of Red Versus White Wine and Cancer Risk: A Meta-Analysis of Observational Studies. Nutrients, 17(3); 534. doi:10.3390/nu17030534.
  • International Agency for Research on Cancer (IARC). Alcohol Consumption and Cancer Risk.
  • World Health Organization (WHO). Global Status Report on Alcohol and Health 2023.

Gluconolactone: A Breakthrough for Targeted Lupus Therapy

0

New research highlights the potential of this naturally occurring compound in restoring immune balance and reducing inflammation in lupus patients.

By Olivier Felicio

A New Approach to Lupus Treatment

Lupus is a chronic autoimmune disease in which the body’s immune system mistakenly attacks its own tissues, leading to widespread inflammation and organ damage. The condition can affect multiple systems, including the skin, joints, kidneys, and nervous system. Traditional treatment options rely on immunosuppressive drugs, which help control disease progression but often come with significant side effects, including increased susceptibility to infections.

A recent study co-led by the University of Zurich (UZH), in collaboration with Harvard Medical School and Beth Israel Deaconess Medical Center, has identified a promising alternative. Researchers found that gluconolactone, a naturally occurring compound, may help restore immune balance in lupus patients without suppressing immune function. This discovery could pave the way for more targeted therapies with fewer adverse effects.

How Gluconolactone Restores Immune Balance 

A key aspect of lupus pathology is the dysfunction of regulatory T cells (Tregs), which normally prevent the immune system from attacking the body’s own tissues. When these cells fail to function properly, unchecked inflammation leads to disease progression.

The study, published in Science Translational Medicine, found that gluconolactone significantly increases both the number and function of Tregs. The research demonstrated:

  • Enhanced Treg production – The compound promoted the formation of these immune-regulating cells in laboratory cultures.
  • Reduction of inflammatory responses – Gluconolactone inhibited two key pro-inflammatory T-helper cell subgroups involved in autoimmune reactions.
  • Improved immune regulation in lupus models – Mice genetically engineered to develop lupus exhibited better Treg function and reduced inflammatory skin rashes after gluconolactone treatment.

Dr Antonios Kolios, a lead researcher in the study and a group leader at the Department of Dermatology at UZH, describes gluconolactone as a “power food” for regulatory T cells. “This is a real win-win situation for immune balance and inflammation control,” he explains.

Beyond laboratory and animal studies, gluconolactone has shown promise in human patients with cutaneous lupus, a form of the disease that primarily affects the skin.

In a clinical study, a topical cream containing gluconolactone led to visible improvements within two weeks. Patients experienced a reduction in skin inflammation without the side effects commonly associated with corticosteroids or immunosuppressive therapies.

This suggests that gluconolactone could be developed into targeted treatments for lupus and other autoimmune conditions, offering a natural and potentially safer alternative to existing medications.

Potential Applications Beyond Lupus

Given its ability to strengthen regulatory T cells and curb excessive immune responses, researchers believe gluconolactone may also be beneficial in treating other autoimmune diseases, including:

  • Psoriasis – a chronic inflammatory skin disorder
  • Rheumatoid arthritis – an autoimmune condition that affects the joints
  • Multiple sclerosis – a disease impacting the nervous system

While the early findings are promising, further clinical trials are necessary to establish gluconolactone’s efficacy across these conditions.

Dr Kolios has already filed a patent for the use of gluconolactone in autoimmune therapies, indicating confidence in its potential as a viable treatment option.

Before gluconolactone-based therapies can be made widely available, additional research is required to validate its long-term safety and effectiveness. The next phase of research will focus on:

  • Larger clinical trials to confirm the compound’s effects in human patients.
  • Comprehensive safety evaluations to rule out potential long-term side effects.
  • Development of different formulations, including oral, injectable, and topical applications, to determine the most effective method of delivery.

While these steps are necessary before regulatory approval, the findings thus far indicate that gluconolactone may represent a new generation of natural, immune-modulating therapies for lupus and other autoimmune diseases.

Researchers have identified gluconolactone as a potential treatment for lupus, offering new hope for targeted immune regulation.

Conclusion

The discovery of gluconolactone’s immune-modulating properties offers new possibilities for lupus treatment. Unlike conventional immunosuppressants, this naturally occurring compound may help regulate immune function without compromising overall immune defences.

While further trials are necessary, the early evidence suggests that gluconolactone could lead to more effective, targeted treatments for lupus and other autoimmune conditions. For patients who struggle with the side effects of current therapies, this research represents a step towards a future with better disease management and improved quality of life.

The scientific community will continue to monitor developments in this area, but the potential of gluconolactone is already generating significant interest in the field of autoimmune research.


Sources:

  • University of Zurich. Gluconolactone restores immune regulation and alleviates skin inflammation in lupus-prone mice and in patients with cutaneous lupus. Science Translational Medicine. (2025).
  • Li, W., et al. doi.org/10.1126/scitranslmed.adp4447.

SurvivorRx Launches Groundbreaking Personalized Wellness Program for Cancer Survivors

0

SurvivorRx Launches Groundbreaking Personalized Wellness Program for Cancer Survivors

SurvivorRx, a pioneering wellness brand designed exclusively for cancer survivors, has officially launched, offering a first-of-its-kind approach to post-treatment health. With a focus on holistic, science-backed support, SurvivorRx provides personalized supplements, expert-driven education, and a thriving community to help survivors regain strength and vitality.

A New Era of Survivor Wellness

Co-founded by Dr. Joe Mignone, a seasoned oncologist with over 25 years of clinical experience, and his wife Marzena Mignone, a dedicated cancer caregiver, SurvivorRx was born from their shared mission to bridge the gap in survivorship care. Their experience revealed a lack of safe, targeted wellness solutions for those navigating life after cancer—many supplements on the market fail to consider survivors’ unique nutritional needs or include ingredients that may be contraindicated for certain cancers.

Determined to change that, the Mignones assembled a team of oncologists, pharmacists, and naturopaths to develop SurvivorRx’s inaugural collection: meticulously formulated supplements that address the critical health concerns of survivors, from immune support to inflammation balance and whole-body wellness.

Tailored Nutrition Backed by Science

SurvivorRx blends cutting-edge Western clinical science with Eastern healing traditions to support survivors’ specific health needs. The debut lineup includes:

  • SurvivorRx ImmunityPlus ($79) – A daily multi-supplement pack for immune and overall health support.
  • Breast Cancer ER+ and ER- Formulas ($119-$129) – Targeted formulations addressing the unique nutritional needs of breast cancer survivors.
  • Prostate Cancer Formula ($119-$139) – Designed for prostate cancer survivors to support optimal recovery and long-term well-being.

Each formula undergoes rigorous testing in FDA-verified, cGMP-certified U.S. facilities and features clinically researched ingredients, such as 3rd Generation Curcumin (backed by over 30 UCLA-led trials), sustained-release melatonin, and patented probiotics. SurvivorRx prioritizes purity, safety, and efficacy, ensuring only the highest-quality supplements reach the hands of those who need them.

A Personal Mission to Empower Survivors

“As an oncologist, I’ve seen firsthand how challenging post-cancer wellness can be,” says Dr. Joe Mignone, Co-Founder of SurvivorRx. “Not all supplements are created equal, and what works for one survivor may not be safe for another. SurvivorRx was created to give cancer survivors personalized solutions they can trust.”

For Marzena Mignone, the journey is personal:
“As a caregiver, I experienced the frustration of navigating survivorship without clear guidance. With Joe’s medical expertise, I was lucky to have direction—but I knew not everyone had that support. SurvivorRx exists to make survivorship easier, healthier, and safer for survivors and their loved ones.”

A Commitment to Survivorship Care

SurvivorRx is more than just supplements—it’s a movement dedicated to reshaping post-cancer wellness. Through education, expert guidance, and a supportive community, the brand aims to empower survivors with the tools they need to thrive beyond treatment.

United Natural Foods, Inc. (NYSE: UNFI) Reports Strong Second Quarter Fiscal 2025 Performance

0

United Natural Foods, Inc. (NYSE: UNFI), a leading distributor of natural, organic, and conventional products, has announced its financial results for the second quarter of fiscal 2025, covering the 13-week period ending 1st February 2025. The company’s performance highlights its commitment to strategic growth, profitability, and operational efficiency, as well as its continued focus on customer and supplier value creation.

With a 4.9% increase in net sales to $8.2 billion, a 13.3% rise in Adjusted EBITDA, and improved free cash flow, UNFI continues to demonstrate resilience and adaptability in the evolving food distribution landscape.

Let’s dive into the key takeaways from UNFI’s latest quarterly results and what they mean for investors, stakeholders, and the broader food distribution industry.

Second Quarter Fiscal 2025: Key Financial Highlights

UNFI’s second-quarter performance shows solid top-line growth and a steady reduction in net loss, despite ongoing industry challenges. Here’s a breakdown of the key financial metrics:

  • Net Sales: $8.2 billion (+4.9% YoY)
  • Net Loss: $(3) million, improved from $(15) million in Q2 FY24
  • Loss Per Share (EPS): $(0.05), compared to $(0.25) in Q2 FY24
  • Adjusted EPS: $0.22, a 214.3% increase from $0.07 in Q2 FY24
  • Adjusted EBITDA: $145 million, up 13.3% YoY
  • Free Cash Flow: $193 million, reflecting a 66.4% improvement from Q2 FY24

The company has raised its full-year fiscal 2025 outlook for all key financial metrics except capital and cloud implementation expenditures, indicating confidence in sustained growth and operational efficiency.

Operational and Strategic Progress

1. Strengthening Customer and Supplier Partnerships

UNFI’s commitment to enhancing customer and supplier value is a core pillar of its multi-year strategic plan. The company is actively working on:

  • product-focused realignment in its wholesale business to deliver more customized service offerings
  • Expanding initiatives that strengthen supplier partnerships, ensuring better product availability and pricing for customers
  • Enhancing supply chain efficiency, evidenced by the successful closure of the Fort Wayne distribution centre in February 2025

2. Lean Management Driving Profitability

UNFI’s lean management approach is yielding positive results, reflected in:

  • Lower operating expenses as a percentage of net sales (12.6% in Q2 FY25 vs. 13.0% in Q2 FY24)
  • A focus on cost-saving initiatives, contributing to higher margins and cash flow improvements
  • Deleveraging efforts, with net debt to Adjusted EBITDA declining to 3.7x, a 0.6x reduction over the past 12 months

3. Sustainable Cash Flow and Capital Allocation

UNFI’s strong free cash flow of $193 million in Q2 FY25 underscores its ability to generate cash while managing expenditures effectively. Key financial management strategies include:

  • reduction in outstanding debt, with total net debt standing at $2.05 billion
  • Interest expense savings, with Q2 FY25 net interest expense at $38 million, down from $40 million in Q2 FY24
  • Maintaining $1.31 billion in liquidity, including $44 million in cash and $1.27 billion in available credit

These measures support future investments in technology, infrastructure, and customer service improvements, ensuring long-term stability and growth.

What’s Next for UNFI? Fiscal 2025 Outlook

Upgraded Full-Year Financial Projections

As a result of its solid first-half performance, UNFI has raised its full-year fiscal 2025 outlook for key financial metrics:

Metric Previous Outlook (Dec 2024) Updated Outlook (Mar 2025)
Net Sales ($B) $30.6 – $31.0 $31.3 – $31.7
Net (Loss) Income ($M) $(31) – $(3) $(13) – $3
EPS $(0.45) – $(0.05) $(0.15) – $0.05
Adjusted EPS $0.40 – $0.80 $0.70 – $0.90
Adjusted EBITDA ($M) $530 – $580 $550 – $580
Free Cash Flow ($M) > $100 > $150

These revised projections reflect UNFI’s confidence in its operational execution, cost efficiencies, and demand trends for natural and organic products.

Continued Execution of Multi-Year Strategy

Looking ahead, UNFI remains focused on:

  • Further enhancing product specialization through its wholesale realignment
  • Improving supply chain efficiency to drive cost savings and better serve customers
  • Identifying new revenue opportunities, particularly within the high-growth natural and organic segment
  • Sustaining profitability while maintaining its commitment to deleveraging and cash flow growth

Challenges and Risks to Watch

While UNFI’s performance has been strong, a few external factors could impact future results:

  • Inflationary pressures on product pricing and operational costs
  • Evolving consumer demand in the natural and organic space
  • Macroeconomic conditions, including interest rate fluctuations affecting debt management

However, UNFI’s strategic cost management and strong industry positioning should help mitigate these risks over time.

How Trade Tensions Are Driving the ‘Buy Canadian’ Movement

0

By Olivier Felicio | Special to IHR Magazine

As trade tensions between Canada and the United States intensify, a new wave of economic patriotism is reshaping consumer habits. With U.S. President Donald Trump imposing fresh tariffs on Canadian goods, consumers are responding with their wallets—actively choosing homegrown products as a form of economic self-preservation and national pride. This shift presents both opportunities and challenges for Canadian retailers and manufacturers, particularly in the natural health sector, where transparency and product sourcing are already top consumer priorities.

Trade Tensions Ignite a Nationwide Shift

On March 4, 2025, the U.S. government implemented a 25% tariff on most Canadian and Mexican imports, escalating an already fraught trade relationship. Trump’s comments about potentially making Canada the 51st U.S. state only added fuel to the fire, prompting widespread consumer backlash.

Recent surveys highlight a significant shift in buying habits:

  • 88% of Canadians say they will prioritize purchasing products labeled as “Made in Canada.”
  • 42% of consumers report actively avoiding U.S. products.
  • 56% of respondents say they would rather stop buying a product altogether than purchase a non-Canadian alternative.

For the natural health industry, this growing consumer loyalty to Canadian-made products is a pivotal moment—one that requires careful strategy to navigate successfully.

The Challenges of a ‘Buy Canadian’ Movement

While consumer sentiment is clear, two major hurdles could impact the long-term sustainability of this movement: cost barriers and labeling confusion.

1. Pricing Pressure: The High Cost of Buying Canadian

Canadian-made products, particularly in the natural health space, often carry a higher price tag. Factors such as domestic labor costs, strict regulatory requirements, and limited economies of scale make it difficult for local manufacturers to compete with cheaper international imports.

The ongoing cost-of-living crisis, which saw grocery prices rise 7.8% in 2023, has already put financial strain on many households. With 71% of Canadians identifying inflation as their top economic concern, convincing consumers to pay a premium for local products will require strategic pricing, bundling, and loyalty incentives.

2. Labeling Confusion: What Does ‘Made in Canada’ Really Mean?

Consumers looking to support Canadian brands face another challenge: distinguishing between “Made in Canada” and “Product of Canada” labels.

  • “Made in Canada” means that the final substantial transformation occurs in Canada, but up to 49% of ingredients can be sourced internationally.
  • “Product of Canada” means that almost all significant ingredients and processing must be Canadian.

This lack of clarity can cause frustration, particularly in the wellness sector, where ingredient origin is a crucial buying factor. To sustain the “Buy Canadian” movement, clearer labeling regulations and consumer education will be key.

The Industry Response: Natural Health Brands Adapt

As consumer demand for Canadian-made products grows, retailers and manufacturers in the natural health space are taking proactive steps:

  • Retailers Are Prioritizing ‘Made in Canada’ Products
    Major grocery and wellness retailers are expanding shelf space for Canadian brands, using in-store signage, digital promotions, and special discounts to highlight domestic products.
  • E-Commerce Platforms Are Driving Awareness
    Online marketplaces like Madeinca.ca are making it easier for consumers to find and purchase verified Canadian health and wellness products.
  • Loyalty Programs Reward Domestic Purchases
    Retailers are introducing exclusive discounts and promotions for customers who prioritize Canadian-made products.
  • Government and Industry Collaboration
    There is mounting pressure on policymakers to support local manufacturing through subsidies, tax breaks, and grants, ensuring domestic producers can scale effectively.

Opportunities for the Natural Health Industry

For businesses in the natural health sector, the “Buy Canadian” movement represents a unique chance to strengthen consumer loyalty and differentiate themselves in a competitive market. Key opportunities include:

  1. Brand Positioning – Companies that emphasize Canadian-sourced ingredients and ethical production can build deeper connections with their customer base.
  2. Retail Partnerships – Collaborating with Canadian retailers can drive targeted promotions and exclusive product launches.
  3. Supply Chain Resilience – Investing in domestic manufacturing can reduce dependency on international supply chains and create long-term sustainability.

Looking Ahead: Is This a Permanent Consumer Shift?

While the current trade tensions may have triggered this wave of economic nationalism, consumer preference for local goods could become a lasting trend—provided businesses address cost concerns and product transparency.

For retailers and manufacturers in the natural health industry, now is the time to capitalize on this shift. With strategic pricing, consumer education, and marketing efforts emphasizing Canadian quality, businesses can strengthen their position in a rapidly evolving marketplace.

The bottom line? Economic patriotism isn’t just a temporary reaction—it’s an opportunity for long-term industry growth.


Olivier Felicio is a business and trade journalist specializing in the natural health and wellness industry. For more insights on industry trends, contact olivier@ihrmagazine.com

Redsenol-1 Plus Listed in NCI Drug Dictionary

0

Canada Royal Enoch Phytomedicine Ltd., a pioneering force in ginseng and ginsenoside research, proudly announces a historic milestone: its premium ginsenoside supplement, Redsenol-1 Plus Noble Ginsenosides, has been officially included in the U.S. National Cancer Institute’s (NCI) Drug Dictionary. This distinction makes Redsenol-1 Plus the first and only product in the global multi-component ginsenoside industry to receive this listing.

Why This Matters: NCI Drug Dictionary Recognition

The NCI Drug Dictionary serves as a gold-standard reference for drugs and agents used in cancer treatment and supportive care. This authoritative database now defines Redsenol-1 Plus as an oral herbal supplement containing sixteen bioactive ginsenosides—including Rg3(R, S), Rh1(S, R), Rh2(R, S), Rk1, Rk3, and more.

What sets Redsenol-1 Plus apart from conventional ginseng extract supplements? Unlike most products that contain large-molecule, poorly absorbed ginsenosides such as Rg1, Rb1, and Rc, Redsenol-1 Plus is formulated with 16 highly bioavailable rare ginsenosides at a concentration of 20%—five times higher than traditional ginseng extracts.

Leading Innovation in Ginsenoside Science

Through proprietary extraction, processing, and transformation technologies, Canada Royal Enoch Phytomedicine has achieved large-scale production of these rare and valuable compounds. This breakthrough positions the company at the forefront of global ginsenoside innovation.

“The inclusion of Redsenol-1 Plus in the NCI Drug Dictionary provides a standardized reference for researchers and clinicians worldwide,” says Dr. Peihua Yu, founder and CEO of Canada Royal Enoch Phytomedicine. “We are committed to advancing scientific understanding of ginsenosides in oncology and beyond.”

Ongoing Clinical Research on Cancer-Related Fatigue

The NCI recognition comes as Canada Royal Enoch Phytomedicine continues its groundbreaking clinical trial on cancer-related fatigue (ClinicalTrials.gov Identifier: NCT05664009). Conducted by KGK Science, Inc., a leading Canadian clinical research organization, this triple-blind, placebo-controlled study investigates the effectiveness of Redsenol-1 Plus in alleviating fatigue—a debilitating symptom experienced by many cancer patients.

METRO Inc. Appoints Nicolas Amyot as New CFO, Succeeding François Thibault

0

METRO Inc. has announced the appointment of Nicolas Amyot as its new Chief Financial Officer (CFO), effective April 18, 2025. Amyot will succeed François Thibault, whose retirement was announced in October 2024.

With nearly 30 years of financial expertise, including 20 years at a major Canadian manufacturing company with global operations, Amyot brings a wealth of strategic financial leadership to METRO. As Vice President, Finance for the past 11 years, he has successfully guided large-scale businesses in achieving financial growth and operational efficiency.

Amyot will officially join METRO on March 17, 2025, as Executive Vice President, Finance, working alongside Thibault to ensure a seamless transition.

Leadership for Growth

METRO’s President and CEO, Eric La Flèche, expressed confidence in Amyot’s appointment:

“I am very pleased to welcome Nicolas to the executive team. His solid experience and proven leadership will support our growth. I would also like to thank François for his great contribution to our success.”

What This Means for Health Retailers

As METRO continues to expand its footprint in grocery and pharmacy retail, Amyot’s financial stewardship is expected to drive profitability, operational efficiencies, and strategic investments—key areas that could benefit METRO’s health and wellness partners. His expertise in navigating complex financial landscapes positions METRO for continued success in Canada’s evolving health retail sector.

For industry professionals, this leadership change signals continued financial stability and growth opportunities within METRO’s extensive retail network, including Jean Coutu and Brunet pharmacy brands.

Supporting Growth at Frankie’s Organic Foods: How Digitization is Driving Productivity

0

The Quebec-based manufacturer, packager, and distributor of USDA-certified organic snacks is embracing digitization to scale operations and boost efficiency, thanks to nearly $1 million in federal funding from Canada Economic Development for Quebec Regions (CED).

With $995,922 in repayable contributions, Frankie’s Organic is modernizing its production lines with cutting-edge robotic equipment, an advanced packaging system, and an intelligent conveyor system. This investment allows the company to streamline its private-label and in-house snack production—ensuring that its products remain gluten-free, GMO-free, and pesticide-free while keeping up with growing demand.

Why This Matters for Health Retailers

For retailers looking to stock high-quality, organic snacks, Frankie’s Organic’s expansion signals greater supply chain reliability and innovation in the industry. As automation enhances efficiency, retailers can expect consistent product availability, improved packaging solutions, and potentially faster turnaround times—key benefits in a market where demand for clean-label, organic snacks is on the rise.

Government Support Fuels SME Growth

Quebec’s economic recovery hinges on regional businesses investing in innovation, and Frankie’s Organic is a prime example. Annie Koutrakis, Member of Parliament for Vimy, emphasized that these investments will strengthen Laval’s economy, while Pascale St-Onge, Minister of Tourism, highlighted how SME-driven innovation fuels broader economic growth.

What’s Next?

With new automation in place, Frankie’s Organic is poised to expand its market reach while staying true to its mission of delivering clean, natural, and transparent snack options. For health retailers, that means a reliable partner in the growing organic food sector—one committed to quality, sustainability, and efficiency.

Nature’s Way Launches Challenge to Support Health and Wellness Breakthroughs

0

A New Era of Science-Backed Innovation for Health Retailers

Health retailers, take note: A major opportunity is unfolding in the world of vitamins and supplements. Nature’s Way, a trusted industry leader for over 50 years, has announced the launch of its Innovation Challenge, a platform designed to fund and mentor scientific pioneers in gut health and weight management. This initiative, open to startups, academics, and researchers across Canada and the U.S., could fuel the next big product innovation to hit your shelves.

Why This Matters for Health Retailers

With consumer interest in gut health and GLP-1 weight wellness solutions surging, retailers need to stay ahead of emerging trends. A 2024 poll found that 12% of U.S. adults have used GLP-1 medications, while 60-70 million Americans struggle with digestive issues. This growing demand presents a unique opportunity for health-focused retailers to expand their offerings with science-backed, nature-derived solutions.

Nature’s Way: A Trusted Partner in Innovation

As part of the Schwabe Group, a global leader in phytomedicine, Nature’s Way has a portfolio of over 700 plant-based products—including bestsellers like Sambucus Gummy, voted #1 Product of the Year by Kantar. With a state-of-the-art facility and a team of food scientists, chemists, and microbiologists, the company is uniquely positioned to transform emerging research into retail-ready products.

How to Get Involved

For health retailers looking to align with the latest in scientifically driven wellness, this initiative signals a pipeline of innovative, evidence-based products coming soon. If you work with startups, researchers, or brands pioneering in gut health and weight management, now’s the time to encourage applications to the Innovation Challenge.

Submissions are open on a rolling basis to U.S. and Canadian innovators.

Selected applicants receive funding and expert mentorship to bring their ideas to market.

Health retailers can anticipate next-generation solutions that meet evolving consumer needs.

By championing scientific breakthroughs, Nature’s Way is setting the stage for the next wave of health retail innovation.